Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21292263 | 1.00 | DYRK1A (0.41) | DYRK1AGSK3BCCR1FPR3FPR2 | |
| SCHEMBL21292360 | 0.89 | PDE7A (0.41) | CNR2PDE7ALMNAKDM4EALDH1A1 | |
| SCHEMBL21292357 | 0.89 | PDE7A (0.41) | CNR2PDE7ALMNAKDM4EALDH1A1 | |
| SCHEMBL21292351 | 0.84 | TRPV1 (0.37) | CNR2CYP3A4LMNAMAPTKDM4E | |
| SCHEMBL21292352 | 0.84 | TRPV1 (0.37) | CNR2CYP3A4LMNAMAPTKDM4E | |
| SCHEMBL21292340 | 0.78 | HTR3A (0.37) | HTR4CNR2CYP3A4LMNAKDM4E | |
| SCHEMBL6507201 | 0.77 | RXRA (0.41) | CNR2LMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL6502144 | 0.76 | RXRA (0.39) | CNR2LMNAMAPTALDH1A1MAPK1 | |
| SCHEMBL21292250 | 0.76 | DYRK1A (0.46) | DYRK1AGSK3BHTR4CNR2CNR1 | |
| SCHEMBL21292249 | 0.76 | DYRK1A (0.46) | DYRK1AGSK3BHTR4CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-3755696-B1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2022-12-22 | — | — | US | disclosed |
| US-10934297-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3755696-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | Samumed, LLC (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-112020501-A | 5-heteroaryl substituted indazol-3-yl carboxamides, their preparation and use | 萨穆梅德有限公司 | 2020-12-01 | — | — | CN | disclosed |
| US-20190263821-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-08-29 | — | — | US | disclosed |
| WO-2019165192-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934297-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | DYRK1A 1/4885GSK3B 11/4885CCR1 3797/4885 |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | DYRK1A 1/4885GSK3B 11/4885CCR1 3797/4885 |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | DYRK1A 1/4885GSK3B 11/4885CCR1 3797/4885 |
| US-20190263821-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | DYRK1A 1/4885GSK3B 11/4885CCR1 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.